Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for COPN.SW and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for COPN.SW and 80,000+ other tickers.
See exactly how COPN.SW's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for COPN.SW and 80,000+ other tickers.
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
Dublin, Ireland--(Newsfile Corp. - July 1, 2026) - Cosmo N.V. (SIX: COPN) ("Cosmo") announced
Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) ("Cosmo") is pleased to make known that its
Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43)
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland--(Newsfile Corp. - April 10, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: